JAK inhibitors are widely used to treat autoimmune and inflammatory conditions, most notably rheumatoid arthritis [6], as well as to alleviate cytokine storm in critically-ill COVID19 patients [6,76–78], suggesting treatment with JAK1 specific inhibitors may even attenuate STAT3-dependent hypertrophy, cytokine production, and immune cell recruitment that could alleviate excessive inflammation and reduce adverse cardiac remodeling in the stressed adult heart. The gene discussed is JAK1; the disease is rheumatoid arthritis.